The Power of Partnerships
As reported by BioPharma Dive, Nanobiotix—a biotechnology company born out of technology licensed by UB—will license an experimental cancer treatment to Johnson & Johnson’s Janssen arm in a deal announced in July, giving the company enough capital to fund operations into 2024.
J&J will pay Nanobiotix $30 million up front and as much as $30 million worth of regulatory and development support for a late-stage clinical trial testing. The treatment, called NBTXR3, is injected into tumors and is designed to boost the effects of radiation therapy. The company is currently testing it in a Phase 3 trial of about 500 patients with head and neck cancer.
Read the full story here.